First Addendum to Roche/CBMX Research and Development Agreement

Contract Categories: Business Operations › Development Agreements
EX-10.17 3 firstamend-roche.htm FIRST ADDENDUM TO ROCHE AGREEMENT First Addendum to Roche Agreement
EXHIBIT 10.17
 
cbmx
COMBIMATRIX
CORPORATION

6500 Harbour Heights Pkwy
Muklteo, WA 98275

Tel ###-###-####
Fax ###-###-####

www.combimatrix.com

Via Overnight Courier
25 March 2003
Stefan Willemsen
Roche Diagnostics GmbH
Nonenwald 2
82377 Penzberg
Germany

First Addendum to Roche/CBMX Research and Development Agreement

Dear Stefan:
As we discussed, we need to update Annex I in the current R&D Agreement to update the project milestones and priorities of the Committee and to add in completed milestones for the sake of completeness.

Please sign both copies of this letter with a revised Annex I to substitute in the revised Annex I.

Sincerely,
Combimatrix Corporation
 
/s/ Jeff Oster
 
Jeff Oster
Sr. Vice President for Intellectual Property

Agreed to substitute revised Annex I
Roche Diagnostics GmbH
 
/s/ Stefan Willemsen
Stefan Willemsen
 

Annex I
Development Program and Payment Schedule


A  1 K System
        
 
 Product  Due Date  Deliverable
Milestone Payment 
In Mio US $
*
 
*
*
 
*
 
 
 
 
*
 
 
 
 
 
 
 
 
 
 
 
*
 
 
 
 
 
 
 
 
 
 
*
 
 
*
 
 
*
 
 
 
*
 
 
 
 
 
 
*
 
 
 
 
 
 
*
 
 
*
 
 
*
 
 
 
*
 
 
 
 
 
 
*
 
 
*
 
 
 
 
 
*
 
 
 
*
 
 
 
 
 
 
 
*
 
* Omitted pursuant to a request for confidential treatment. The omitted material has been filed separately with the SEC.
 
*
 
 
 
 
*
 
 
 
 
 
 
*
 
*
 
 
 
 
 
 
*
 
 
*
 
 
 
 
 
*
*
 
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
 
 
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
 
 
 
 
*
 
*
 
 
 
*
 
 
*
 
  
 
*
 
 
 
 
*
 
 
 
*
 
 
 
 
*
 
 
 
*
*
 
 
 
 
 
 
 
 
*
*
 
* Omitted pursuant to a request for confidential treatment. The omitted material has been filed separately with the SEC.
 
*
*
*
 
 
*
 
*
 
*
 
 
 
*
*
 
 
 
*
 
 
 
*
 
*
 
 
 
*
 
 


B

10 K System and other development projects

*
 
*
*
 
 
*
 
 
*
 
 
 
*
*
 
 
*
*
 
 
 
*
*
 
  
*
 
*
 
 
*
*
 
 
*
 
  

* Omitted pursuant to a request for confidential treatment. The omitted material has been filed separately with the SEC.